Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma

Cancer
Manish S BhandariDavid C Smith

Abstract

The current study evaluated the efficacy of oral uracil/tegafur (UFT) and leucovorin (LV) in patients with hormone-refractory metastatic prostate carcinoma. Twenty-eight patients with hormone-refractory metastatic carcinoma of the prostate who had undergone antiandrogen withdrawal and no more than 1 prior chemotherapy treatment were enrolled on a single-institution Phase II trial. Patients were treated with oral UFT at a dose of 300 mg/m2/d and oral LV at a dose of 90 mg/day for 28 days followed by 7 days off therapy on a 35-day cycle regimen. Twenty-six patients were evaluable for response and toxicity. There was no response by objective criteria in 9 patients with measurable disease. Four responses by prostate-specific antigen (PSA) criteria (i.e., PSA decrease by > 50%) were noted (15%) lasting a mean of 20.5 weeks. Therapy was generally well tolerated, with 2 patients developing Grade 4 toxicity (1 patient each with diarrhea and hand-foot syndrome) and 4 patients having significant Grade 3 toxicity (anemia, hyperbilirubinemia, and vomiting) (Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria). Six patients had stable disease by clinical, laboratory, and radiologic criteria for an average...Continue Reading

References

Jan 1, 1992·Journal of Cancer Research and Clinical Oncology·D SinghJ Cho
Jan 1, 1988·Cancer Chemotherapy and Pharmacology·K OtaK Kimura
Feb 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F J AnsfieldJ P Singson
Sep 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M BrausiA Pawinski
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R PazdurB Bready
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H WadaT Teramatsu
Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I F TannockK C Murphy
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G LiuE Warner
Apr 29, 1998·Cancer Investigation·R PazdurD H Ho
Nov 1, 1993·British Journal of Urology·D RaghavanJ J Grygiel
Apr 14, 1999·CA: a Cancer Journal for Clinicians·S H LandisP A Wingo
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P W KantoffN J Vogelzang
Sep 17, 2002·British Journal of Cancer·R PetrioliG Francini
Apr 1, 2004·British Journal of Cancer·R MorantH-P Schmid
Apr 23, 2004·The New England Journal of Medicine·Harubumi KatoUNKNOWN Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.